Skip to main content
SpringerLink
Log in

The Role of Phytoestrogens as Cancer Prevention Agents

  • Chapter
Cancer Chemoprevention

Part of the book series: Cancer Drug Discovery and Development ((CDD&D))

Abstract

The addition or withdrawal of estrogenic substances from a patient’s milieu as part of the prevention or treatment of cancer has been a part of modern medicine for over 100 years. It began in 1896 with surgical resection of the ovaries, the principal site of synthesis of physiologic estrogens, as a treatment for breast cancer by British surgeon Sir George Beatson (1). This method has been recently advanced as a prophylactic treatment for women at very high risk for breast cancer who have BRCA-1 and BRCA-2 germline mutations (2,3).

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 299.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Beatson GT. On the treatment of inoperable cases of carcinoma of the mamma: suggestions for a new method of treatment, with illustrative cases. Lancet 1896;2:104–107,162–165.

    Article  Google Scholar 

  2. Kauff ND, Satagopan JM, Robson ME, et al. Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med 2002;346:1609–1615.

    Article  PubMed  Google Scholar 

  3. Rebbeck TR, Lynch HT, Neuhausen SL, et al. The Prevention and Observation of Surgical End Points Study Group. Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N Engl J Med 2002;346:1616–1622.

    Article  PubMed  Google Scholar 

  4. Haddow A, Watkinson JM, Pattérson E, Koller PC. Influence of synthetic estrogens upon advanced malignant disease. Br Med J 1944;2:393–398.

    Article  PubMed  CAS  Google Scholar 

  5. Meites J, Cassell E, Clark J. Estrogen inhibition of mammary tumor growth in rats: counteraction by prolactin. Proc Soc Exp Biol Med 1971;137:1225–1227.

    PubMed  CAS  Google Scholar 

  6. Jordan C. Historical perspective on hormonal therapy of advanced breast cancer. Clin Ther 2002;24:A3–A16.

    Article  PubMed  CAS  Google Scholar 

  7. Fabian CJ, Kimler BF. Beyond tamoxifen: new endpoints for breast cancer chemoprevention, new drugs for breast cancer prevention. Ann NY Acad Sci 2001;952:44–59.

    Article  PubMed  CAS  Google Scholar 

  8. Parkin DM, Pisani P, Ferlay J. Estimates of the worldwide incidence of eighteen major cancers in 1985. Int J Cancer 54;1993:594–606.

    Article  PubMed  CAS  Google Scholar 

  9. Wu AH. Soy and risk of hormone-related and other cancers. Adv Exp Med Biol 2001;492:19–28.

    Article  PubMed  CAS  Google Scholar 

  10. Shimizu H, Ross RK, Bernstein L, et al. Cancers of the prostate and breast among Japanese and white immigrants in Los Angeles County. Br J Cancer 1991;63:963–966.

    Article  PubMed  CAS  Google Scholar 

  11. Willett WC. Diet, nutrition, and avoidable cancer. Environ Health Perspect 1995;103 (Suppl 8):165–170.

    Article  PubMed  Google Scholar 

  12. Wakai K, Suzuki S, Ohno Y, et al. Epidemiology of breast cancer in Japan. Int J Epidemiol 1995;24:285–291.

    Article  PubMed  CAS  Google Scholar 

  13. Coward L, Barnes NC, Setchell KDR, Barnes S. The antitumor isoflavones, genistein and daidzein, in soybean foods of American and Asian diets. J Agric Food Chem 1993;41:1961–1967.

    Article  CAS  Google Scholar 

  14. Messina M, Barnes S. Workshop report from the Division of Cancer Etiology, National Cancer Institute, National Institutes of Health. The role of soy products in reducing risks of certain cancers. J Natl Cancer Inst 1991;83:541–546.

    Article  PubMed  CAS  Google Scholar 

  15. Messina M, Persky V, Setchell KDR, Barnes S. Soy intake and cancer risk: a review of in vitro and in vivo data. Nutr Cancer 1994;21:113–131.

    Article  PubMed  CAS  Google Scholar 

  16. Messina M, Gardner C, Barnes S. Gaining insight into the health effects of soy but a long way still to go: commentary on the fourth International Symposium on the Role of Soy in Preventing and Treating Chronic Disease. J Nutr 2002;132:547S-551S.

    PubMed  Google Scholar 

  17. Degen GH, Janning P, Diel P, Bolt HM. Estrogenic isoflavones in rodent diets. Toxicol Lett 2002;128:145–157.

    Article  PubMed  CAS  Google Scholar 

  18. Barnes S. Phytoestrogens and breast cancer. Baillieres Clin Endocrinol Metab 1998;12:559–579.

    Article  PubMed  CAS  Google Scholar 

  19. Pike AC, Brzozowski AM, Hubbard RE, et al. Structure of the ligand-binding domain of oestrogen receptor beta in the presence of a partial agonist and a full antagonist. EMBO J 1999;18:4608–4618.

    Article  PubMed  CAS  Google Scholar 

  20. Griffiths K, Denis L, Turkes A, Morton MS. Phytoestrogens and diseases of the prostate gland. Baillieres Clin Endocrinol Metab 1998;12:625–647.

    Article  PubMed  CAS  Google Scholar 

  21. Kim H, Peterson TG, Barnes S. Mechanisms of action of the soy isoflavone genistein: emerging role for its effects via transforming growth factor beta signaling pathways. Am J Clin Nutr 1998;68:1418S–1425S.

    PubMed  CAS  Google Scholar 

  22. Lamartiniere CA, Zhang JX, Cotroneo MS. Genistein studies in rats: potential for breast cancer prevention and reproductive and developmental toxicity. Am J Clin Nutr 1998;68:1400S–1405S.

    PubMed  CAS  Google Scholar 

  23. Lamartiniere CA. Protection against breast cancer with genistein: a component of soy. Am J Clin Nutr 2000;71:1705S–1707S.

    PubMed  CAS  Google Scholar 

  24. Barnes S, Boersma B, Patel R, et al. Isoflavonoids and chronic disease: mechanisms of action. Biofactors 2000;12:209–215.

    Article  PubMed  CAS  Google Scholar 

  25. Hilakivi-Clarke L, Cho E, deAssis S, et al. Maternal and prepubertal diet, mammary development and breast cancer risk. J Nutr 2001;131:154S–157S.

    PubMed  CAS  Google Scholar 

  26. Woods CE, Barnes S, Cline JM, in Phytoestrogen action in the breast and uterus. Phytoestrogens and Health. Gilani GS, Anderson JJB, eds. AOCS Press, Champaign, IL, 2002, pp.440–469.

    Google Scholar 

  27. Sarkar FH, Li YW. Mechanisms of cancer chemoprevention by soy isoflavone genistein. Cancer Metastasis Rev 2002;21:265–280.

    Article  PubMed  CAS  Google Scholar 

  28. Humfrey CD. Phytoestrogens and human health effects: weighing up the current evidence. Nat Toxins 1998;6:51–59.

    Article  PubMed  CAS  Google Scholar 

  29. North American Menopause Society. The role of isoflavones in menopausal health: consensus opinion of The North American Menopause Society. Menopause 2000;7:215–229.

    Article  Google Scholar 

  30. Lawrence JA, Malpas PB, Sigman CC, Kelloff GJ. Clinical development of estrogen modulators for breast cancer chemoprevention in premenopausal vs. postmenopausal women. J Cell Biochem 2000;Suppl 34:103–114.

    Article  CAS  Google Scholar 

  31. Vincent A, Fitzpatrick LA. Soy isoflavones: are they useful in menopause? Mayo Clin Proc 2000;75:1174–1184.

    Article  PubMed  CAS  Google Scholar 

  32. Wang HK. The therapeutic potential of flavonoids. Exp Opin Invest Drugs 2000;9:2103–2119.

    Article  CAS  Google Scholar 

  33. Wiseman H. The therapeutic potential of phytoestrogens. Exp Opin Invest Drugs 2000;9:1829–1840.

    Article  CAS  Google Scholar 

  34. Wagner JD, Anthony MS, Cline JM. Soy phytoestrogens: research on benefits and risks. Clin Obstet Gynecol 2001;44:843–852.

    Article  PubMed  CAS  Google Scholar 

  35. Messina MJ, Loprinzi CL. Soy for breast cancer survivors: a critical review of the literature. J Nutr 2001:131:3095S–3108S.

    PubMed  CAS  Google Scholar 

  36. This B, De La Rochefordiere A, Clough K, et al. The Breast Cancer Group of the Institut Curie. Phytoestrogens after breast cancer. Endocr Rel Cancer 2001;8:129–134.

    Article  CAS  Google Scholar 

  37. Tsourounis C Clinical effects of phytoestrogens. Clin Obstet Gynecol 2001;44:836–842.

    Article  Google Scholar 

  38. Brzezinski A, Debi A. Phytoestrogens: the “natural” selective estrogen receptor modulators? Eur J Obstet Gynecol Reprod Biol 1999;85:47–51.

    Article  PubMed  CAS  Google Scholar 

  39. Baker VL, Leitman D, Jaffe RB. Selective estrogen receptor modulators in reproductive medicine and biology. Obstet Gynecol Sury 2000;55:S21–S47.

    Article  CAS  Google Scholar 

  40. Huber J. Phytoestrogens and SERMS, alternatives to classical hormone therapy? Ther Umsch 2000; 57: 651–654.

    Article  CAS  Google Scholar 

  41. Bush TL, Blumenthal R, Lobo R, Clarkson TB. SERMS and cardiovascular disease in women. How do these agents affect risk? Postgrad Med 2001;Spec No:17–24.

    Google Scholar 

  42. National Heart, Lung, and Blood Institute. NHLBI stops trial of estrogen plus progestin due to increased breast cancer risk, lack of overall benefits. http://www.nhlbi.nih.gov/new/press/02–07–09.htm

    Google Scholar 

  43. Kolata G. Race to fill void in menopause-drug market. NY Times, Sep 1, 2002.

    Google Scholar 

  44. Barnes, S. Phytoestrogens and osteoporosis-what is a safe dose? Br J Nutr 2002 in press.

    Google Scholar 

  45. Morabito N, Crisafulli A, Vergara C, et al. Effects of genistein and hormone-replacement therapy on bone loss in early postmenopausal women: a randomized doubleblind placebo-controlled study. J Bone Mineral Res 2002;17:1904–1912.

    Article  CAS  Google Scholar 

  46. Albertazzi P, Pansini F, Bottazzi M, et al. Dietary soy supplementation and phytoestrogen levels. Obstet Gynecol 1999;94:229–231.

    Article  PubMed  CAS  Google Scholar 

  47. Faure ED, Chantre P, Mares P. Effects of a standardized soy extract on hot flushes: a multicenter, double-blind, randomized, placebo-controlled study. Menopause 2002; 9;5:329–334.

    Article  PubMed  Google Scholar 

  48. Kim H, Xia H, Li L, Gewin J. Attenuation of neurodegeneration-relevant modifications of brain proteins by dietary soy. Biofactors 2000;12:243–250.

    Article  PubMed  CAS  Google Scholar 

  49. de Kleijn MJ, van der Schouw YT, Wilson PW, et al. Dietary intake of phytoestrogens is associated with a favorable metabolic cardiovascular risk profile in postmenopausal US women: the Framingham study. J Nutr 2002;132:276–282.

    PubMed  Google Scholar 

  50. White LR, Petrovitch H, Ross GW, et al. Brain aging and midlife tofu consumption. J Am Coll Nutr 2000;19:242–255.

    PubMed  CAS  Google Scholar 

  51. Sirtori CR. Risks and benefits of soy phytoestrogens in cardiovascular diseases, cancer, climacteric symptoms and osteoporosis. Drug Safety 2001;24:665–682.

    Article  PubMed  CAS  Google Scholar 

  52. Van Patten CL, Olivotto IA, Chambers GK, et al. Effect of soy phytoestrogens on hot flashes in postmenopausal women with breast cancer: a randomized, controlled clinical trial. J Clin Oncol 2002;20:1449–1455.

    Article  PubMed  Google Scholar 

  53. Kuiper GG, Carlsson B, Grandien K, et al. Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors α and β. Endocrinology 1997;138:863–870.

    Article  PubMed  CAS  Google Scholar 

  54. Lamartiniere CA, Cotroneo MS, Fritz WA, et al. Genistein chemoprevention: timing and mechanisms of action in murine mammary and prostate. J Nutr 2002;132:552S–558S.

    PubMed  Google Scholar 

  55. Jordan VC, Gottardis MM, Robinson SP, Friedl A. Immune-deficient animals to study “hormone-dependent” breast and endometrial cancer. J Steroid Biochem 1989;34:169–176.

    Article  PubMed  CAS  Google Scholar 

  56. Grubbs CJ, Juliana MM, Hill DL, Whitaker LM. Effect of laboratory diets on methylnitrosourea-induced mammary cancers and the efficacy of a chemopreventive agent (retinyl acetate). Proc Am Assoc Cancer Res 1986;28:160.

    Google Scholar 

  57. Barnes S, Grubbs C, Setchell KDR, Carlson J. Soybeans inhibit mammary tumors in models of breast cancer. Prog Clin Biol Res 1990;347:239–253.

    PubMed  CAS  Google Scholar 

  58. Hawrylewicz EJ, Zapata J, Blair WH. Soy and experimental cancer: animal studies. J Nutr 1995;125:698S–708S.

    PubMed  CAS  Google Scholar 

  59. Lamartiniere CA, Moore J, Holland M, Barnes, S. Genistein and chemoprevention of breast cancer. Proc Soc Exp Biol Med 1995;208:120–123.

    PubMed  CAS  Google Scholar 

  60. Fritz WA, Coward L, Wang J, Lamartiniere CA. Dietary genistein: perinatal mammary cancer prevention, bioavailability and toxicity testing in the rat. Carcinogenesis 1998;19:2151–2158.

    Article  PubMed  CAS  Google Scholar 

  61. Murrill WB, Brown NM, Zhang J-X, et al. Prepubertal genistein exposure suppresses mammary cancer and enhances gland differentiation in rats. Carcinogenesis 1996;17:1451–1457.

    Article  PubMed  CAS  Google Scholar 

  62. Brown NM, Lamartiniere CA. Xenoestrogens alter mammary gland differentiation and cell proliferation in the rat. Environ Health Perspect 1995;103:708–713.

    PubMed  CAS  Google Scholar 

  63. Cotroneo MS, Wang J, Fritz WA, et al. Genistein action in the prepubertal mammary gland in a chemoprevention model. Carcinogenesis 2002;23:1467–1474.

    Article  PubMed  CAS  Google Scholar 

  64. Wu AH, Wan P, Hankin J, et al. Adolescent and adult soy intake and risk of breast cancer in Asian-Americans. Carcinogenesis 2002;23:1491–1496.

    Article  PubMed  CAS  Google Scholar 

  65. Lubet RL, Steele VE, Barnes S, et al. Chemopreventive effects of genistein on methylnitrosourea (MNU)-induced mammary tumors. AACR Annual Meeting. Proc Am Assoc Cancer Res 2000;41:845, abst 5364.

    Google Scholar 

  66. Manzotti C, Audisio RA, Pratesi G. Importance of orthotopic implantation for human tumors as model systems: relevance to metastasis and invasion. Clin Exp Metastasis 1993;11:5–14.

    Article  PubMed  CAS  Google Scholar 

  67. Hsieh CY, Santell RC, Haslam SZ, Helferich WG. Estrogenic effects of genistein on the growth of estrogen receptor-positive human breast cancer (MCF-7) cells in vitro and in vivo. Cancer Res 1998;58:3833–3838.

    PubMed  CAS  Google Scholar 

  68. Zava DT, Blen M, Duwe G. Estrogenic activity of natural and synthetic estrogens in human breast cancer cells in culture. Environ Health Perspect 1997;105 (Suppl 3):637–645.

    Article  PubMed  CAS  Google Scholar 

  69. Willard ST, Frawley LS. Phytoestrogens have agonistic and combinatorial effects on estrogen-responsive gene expression in MCF-7 human breast cancer cells. Endocrine 1998;8:117–121.

    Article  PubMed  CAS  Google Scholar 

  70. Wang C, Kurzer MS. Effects of phytoestrogens on DNA synthesis in MCF-7 cells in the presence of estradiol or growth factors. Nutr Cancer 1998;31:90–100.

    Article  PubMed  CAS  Google Scholar 

  71. Peterson TG, Barnes S. Genistein inhibition of the growth of human breast cancer cells: independence from estrogen receptors and the multi-drug resistance gene. Biochem Biophys Res Commun 1991;179:661–667.

    Article  PubMed  CAS  Google Scholar 

  72. Peterson TG, Barnes S. Genistein inhibits both estrogen and growth factor stimulated proliferation of human breast cancer cells. Cell Growth Differ 1996;7:1345–1351.

    PubMed  CAS  Google Scholar 

  73. Allred CD, Allred KF, Ju YH, et al. Soy diets containing varying amounts of genistein stimulate growth of estrogendependent (MCF-7) tumors in a dose-dependent manner. Cancer Res 2001;61:5045–5050.

    PubMed  CAS  Google Scholar 

  74. Allred CD, Ju YH, Allred KF, et al. Dietary genistin stimulates growth of estrogen-dependent breast cancer tumors similar to that observed with genistein. Carcinogenesis 2001;22:1667–1673.

    Article  PubMed  CAS  Google Scholar 

  75. Ju YH, Allred CD, Allred KF, et al. Physiological concentrations of dietary genistein dose-dependently stimulate growth of estrogen-dependent human breast cancer (MCF-7) tumors implanted in athymic nude mice. J Nutr 2001;131:2957–2962.

    PubMed  CAS  Google Scholar 

  76. Mizunuma H, Kanazawa K, Ogura S, et al. Anticarcinogenic effects of isoflavones may be mediated by genistein in mouse mammary tumor virus-induced breast cancer. Lab Investig 2002;62:78–84.

    CAS  Google Scholar 

  77. Jin ZM, MacDonald RS. Soy isoflavones increase latency of spontaneous mammary tumors in mice. J Nutr 2002;132:3186–3190.

    PubMed  CAS  Google Scholar 

  78. Lamartiniere CA, Wang J, Smith-Johnson M, Eltoum IE. Daidzein: bioavailability, potential for reproductive toxicity, and breast cancer chemoprevention in female rats. Toxicol Sci 2002;65:228–238.

    Article  PubMed  CAS  Google Scholar 

  79. Yan L, Li DH, Yee JA. Dietary supplementation with isolated soy protein reduces metastasis of mammary carcinoma cells in mice. Clin Exp Metastasis 2002,19;6:535–540.

    Article  PubMed  CAS  Google Scholar 

  80. Martin KA. Hormone replacement therapy. http://cme.med.harvard.edu/syl/martin/l.html

  81. Ju YH, Doerge DR, Allred KF, et al. Dietary genistein negates the inhibitory effect of tamoxifen on the growth of estrogen-dependent human breast cancer (MCF-7) cells implanted in athymic mice. Cancer Res 2002;62:2474–2477.

    PubMed  CAS  Google Scholar 

  82. Boersma B, Barnes S, Kirk M, et al. Soy isoflavonoids and cancer-metabolism at the target site. Mutat Res 2001;480:121–127.

    Article  PubMed  Google Scholar 

  83. Jones JL, Daley BJ, Enderson BL, et al. Genistein inhibits tamoxifen effects on cell proliferation and cell cycle arrest in T47D breast cancer cells. Am Surgeon 2002;68:575–578.

    PubMed  Google Scholar 

  84. Gotoh T, Yamada K, Yin H, et al. Chemoprevention of N-nitroso-N-methylurea-induced rat mammary carcinogenesis by soy foods or biochanin A. Jpn J Cancer Res 1998;89:137–142.

    Article  PubMed  CAS  Google Scholar 

  85. Constantinou AI, Xu H, Lucas LM, Lanvit D. Soy enhances tamoxifen’s cancer chemopreventive effects in female rats. J Nutr 2002;132:576S–577S.

    Google Scholar 

  86. Shen F, Xue X, Weber G. Tamoxifen and genistein synergistically down-regulate signal transduction and proliferation in estrogen receptor-negative human breast carcinoma MDA-MB-435 cells. Anticancer Res 1999;19:1657–1662.

    PubMed  CAS  Google Scholar 

  87. Tanos V, Brzezinski A, Drize O, et al. Synergistic inhibitory effects of genistein and tamoxifen on human dysplastic and malignant epithelial breast cells in vitro. Eur J Obstet Gynecol Reprod Biol 2002:102:188–194.

    Article  PubMed  CAS  Google Scholar 

  88. Peterson TG, Barnes S. Isoflavones inhibit the growth of human prostate cancer cell lines without inhibiting epidermal growth factor receptor autophosphorylation. Prostate 1993; 22:335–345.

    Article  PubMed  CAS  Google Scholar 

  89. Sharma OP, Adlercreutz H, Strandberg JD, et al. Soy of dietary source plays a preventive role against the pathogenesis of prostatitis in rats. J Steroid Biochem Mol Biol 1992;43:557–564.

    Article  PubMed  CAS  Google Scholar 

  90. Aronson WJ, Tymchuk CN, Elashoff RM, et al. Decreased growth of human prostate LNCaP tumors in SCID mice fed a low-fat, soy protein diet with isoflavones. Nutr Cancer 1999;35:130–136.

    Article  PubMed  CAS  Google Scholar 

  91. Zhou JR, Yu LY, Zhong Y, et al. Inhibition of orthotopic growth and metastasis of androgen-sensitive human prostate tumors in mice by bioactive soybean components. Prostate 2002;53:143–153.

    Article  PubMed  CAS  Google Scholar 

  92. Pollard M, Wolter W, Sun L. Prevention of induced prostate-related cancer by soy protein isolate/isoflavonesupplemented diet in Lobund-Wistar rats. In Vivo 2000;14:389–392.

    PubMed  CAS  Google Scholar 

  93. Schleicher RL, Lamartiniere CA, Zheng M, Zhang M. The inhibitory effect of genistein on the growth and metastasis of a transplantable rat accessory sex gland carcinoma. Cancer Lett 1999;136:195–201.

    Article  PubMed  CAS  Google Scholar 

  94. Wang J, Eltoum I-E, Lamartiniere CA. Dietary genistein suppresses chemically-induced prostate cancer in Lobund-Wistar rats. Cancer Lett 2002;186:11–18.

    Article  PubMed  CAS  Google Scholar 

  95. Greenberg NM, DeMayo F, Finegold MJ, et al. Prostate cancer in a transgenic mouse. Proc Natl Acad Sci USA 1995;92:3439–3443.

    Article  PubMed  CAS  Google Scholar 

  96. Gingrich JR, Greenberg NM. A transgenic mouse prostate cancer model. Toxicol Pathol 1996;24:502–504.

    Article  PubMed  CAS  Google Scholar 

  97. Gingrich JR, Barrios RJ, Kattan MW, et al. Androgenindependent prostate cancer progression in the TRAMP model. Cancer Res 1997;57:4687–4691.

    PubMed  CAS  Google Scholar 

  98. Mentor-Marcel R, Lamartiniere CA, Eltoum IE, et al. Genistein in the diet reduces the incidence of poorly differentiated prostatic adenocarcinoma in transgenic mice (TRAMP). Cancer Res 2001;61:6777–6782.

    PubMed  CAS  Google Scholar 

  99. Naciff JM, Jump ML, Torontali SM, et al. Gene expression profile induced by 17a-ethinyl estradiol, bisphenol A, and genistein in the developing female reproductive system of the rat. Toxicol Sci 2002;68:184–199.

    Article  PubMed  CAS  Google Scholar 

  100. Li YW, Sarkar FH. Down-regulation of invasion and angiogenesis-related genes identified by cDNA microarray analysis of PC3 prostate cancer cells treated with genistein. Cancer Lett 2002;186:157–164.

    Article  PubMed  CAS  Google Scholar 

  101. McLachlan JA, Burow M, Chiang TC, Li SF. Gene imprinting in developmental toxicology: a possible interface between physiology and pathology. Toxicol Lett 2001;120:161–164.

    Article  PubMed  CAS  Google Scholar 

  102. Day JK, Bauer AM, DesBordes C, et al. Genistein alters methylation patterns in mice. J Nutr 2002;132(8 Suppl):2419S–2423S.

    PubMed  CAS  Google Scholar 

  103. Lamartiniere CA, Cotroneo MS, Fritz WA, et al. Genistein chemoprevention: timing and mechanisms of action in murine mammary and prostate. J Nutr 2002;132:552S–558S.

    PubMed  Google Scholar 

Download references

Authors
  1. Stephen Barnes PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Coral A. Lamartiniere PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. National Institutes of Health, Rockville, MD, USA

    Gary J. Kelloff MD  & Ernest T. Hawk MD, MPH  & 

  2. CCS Associates, Mountain View, CA, USA

    Caroline C. Sigman PhD

Rights and permissions

Reprints and permissions

Copyright information

© 2004 Springer Science+Business Media New York

About this chapter

Cite this chapter

Barnes, S., Lamartiniere, C.A. (2004). The Role of Phytoestrogens as Cancer Prevention Agents. In: Kelloff, G.J., Hawk, E.T., Sigman, C.C. (eds) Cancer Chemoprevention. Cancer Drug Discovery and Development. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-59259-767-3_24

Download citation

  • DOI: https://doi.org/10.1007/978-1-59259-767-3_24

  • Publisher Name: Humana Press, Totowa, NJ

  • Print ISBN: 978-1-61737-342-8

  • Online ISBN: 978-1-59259-767-3

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation